Renesas Reports Financial Results for the Second Quarter Ended June 30, 2025
Summary of Consolidated Financial Results (Note 1)
Summary of Consolidated Financial Results (Non-GAAP basis) (Note 2)
Three months ended
June 30, 2025
Six months ended
June 30, 2025
Billion yen
% of Revenue
Billion yen
% of Revenue
Revenue
324.6
100.0
633.4
100.0
Gross profit
184.4
56.8
359.6
56.8
Operating profit
91.9
28.3
175.7
27.7
Profit attributable to owners of parent
77.8
24.0
151.1
23.9
EBITDA (Note 3)
110.2
33.9
213.7
33.7
Expand
Summary of Consolidated Financial Results (IFRS basis)
Reconciliation of Non-GAAP gross profit to IFRS gross profit and Non-GAAP operating profit to IFRS operating profit
(Billion yen)
(Note)
1.
All figures are rounded to the nearest 100 million yen.
2.
Non-GAAP figures are calculated by removing or adjusting non-recurring items and other adjustments from GAAP (IFRS) figures following a certain set of rules. The Group believes non-GAAP measures provide useful information in understanding and evaluating the Group's constant business results.
3.
Operating profit + Depreciation and amortization.
4.
Non-recurring revenue that the Group has determined should be excluded
5.
'Other reconciliation items in non-recurring expenses and adjustments' includes the non-recurring items related to acquisitions and other adjustments as well as non-recurring profits or losses the Group believes to be applicable.
Expand
Consolidated Financial Results for the Second Quarter Ended June 30, 2025
English translation from the original Japanese-language document
July 25, 2025
(Amounts are rounded to the nearest million yen)
1. Consolidated financial results for the six months ended June 30, 2025
1.1 Consolidated financial results
(% of change from corresponding period of the previous year)
Revenue
Operating
profit
Profit
before tax
Profit
Profit attributable to owners of parent
Total comprehensive income
Million
yen
%
Million
yen
%
Million
yen
%
Million
yen
%
Million
yen
%
Million
yen
%
Six months ended June 30, 2025
634,311
(10.7)
61,301
(58.4)
(169,288)
－
(175,321)
－
(175,342)
－
(475,677)
－
Six months ended June 30, 2024
710,597
(2.4)
147,508
－
165,985
－
139,743
－
139,587
－
496,716
－
Expand
Basic earnings
per share
Diluted earnings
per share
Yen
Yen
Six months ended June 30, 2025
(97.34)
(97.34)
Six months ended June 30, 2024
78.25
77.20
Expand
(Note)
1.
The Group finalized the provisional accounting treatment for the business combination at the end of December 31, 2024, and each figure for the six months ended June 30, 2024 reflects the details of the finalization of the provisional accounting treatment.
2.
Diluted earnings per share is the same as basic earnings per share as there were no dilutive potential common shares outstanding for the six months ended June 30, 2025.
Expand
1.2 Consolidated financial position
Total assets
Total equity
Equity attributable to owners
Ratio of equity attributable to owners
Million yen
Million yen
Million yen
%
June 30, 2025
3,872,164
2,036,305
2,031,527
52.5
December 31, 2024
4,490,436
2,542,298
2,537,382
56.5
Expand
2. Cash dividends
Cash dividends per share
At the end of
first quarter
At the end of second quarter
At the end of third quarter
At the end of year
Total
Yen
Yen
Yen
Yen
Yen
Year ended
December 31, 2024
0.00
0.00
0.00
28.00
28.00
Year ending
December 31, 2025
0.00
0.00
Year ending
December 31, 2025 (forecast)
---
---
---
Expand
(Note)
Change in forecast of cash dividends since the most recently announced forecast: No
Expand
3. Forecast of consolidated results for the nine months ending September 30, 2025
(% of change from corresponding period of the previous year)
(Note)
1.
The Group reports its consolidated forecast on a quarterly basis (cumulative quarters) as substitute for a yearly forecast in a range format. The non-GAAP gross margin and the non-GAAP operating margin forecasts are provided assuming the midpoint in the non-GAAP revenue forecast.
2.
Non-GAAP figures are calculated by removing or adjusting non-recurring items and other adjustments from GAAP (IFRS) figures following a certain set of rules. The Group believes non-GAAP measures provide useful information in understanding and evaluating the Group's constant business results, and therefore forecasts are provided on a non-GAAP basis.
Expand
4. Others
4.1
Changes in significant subsidiaries for the six months ended June 30, 2025: No
4.2
Changes in Accounting Policies, Changes in Accounting Estimates and Corrections of Prior Period Errors
1.
Changes in accounting policies with revision of accounting standard: No
2.
Changes in accounting policies except for 4.2.1: No
3.
Changes in accounting estimates: Yes
(Note) For details, please refer to P.12 '(Changes in Accounting Estimates)' in the 'Condensed Interim Consolidated Financial Statements, (5) Notes to Condensed Interim Consolidated Financial Statements.'
4.3
Number of shares issued and outstanding (common stock)
1.
Number of shares issued and outstanding (including treasury stock)
As of June 30, 2025:
1,870,614,885 shares
As of December 31, 2024:
1,870,614,885 shares
2.
Number of treasury stock
As of June 30, 2025:
61,430,002 shares
As of December 31, 2024:
75,848,895 shares
3.
Average number of shares issued and outstanding
Six months ended June 30, 2025:
1,801,305,034 shares
Six months ended June 30, 2024:
1,783,808,662 shares
(Note)
Information regarding the implementation of audit procedures: These financial results are not subject to interim review procedures by the independent auditor.
Expand
Cautionary Statement
The Group will hold an earnings conference for institutional investors and analysts on July 25, 2025. The Group plans to post the materials which are provided at the meeting, on the Group's website on that day.
The statements with respect to the financial outlook of Renesas Electronics Corporation (hereinafter 'the Company') and its consolidated subsidiaries (hereinafter 'the Group') are forward-looking statements involving risks and uncertainties. We caution you in advance that actual results may differ materially from such forward-looking statements due to changes in several important factors.
Expand
About Renesas Electronics Corporation
Renesas Electronics Corporation (TSE: 6723) empowers a safer, smarter and more sustainable future where technology helps make our lives easier. A leading global provider of microcontrollers, Renesas combines our expertise in embedded processing, analog, power and connectivity to deliver complete semiconductor solutions. These Winning Combinations accelerate time to market for automotive, industrial, infrastructure and IoT applications, enabling billions of connected, intelligent devices that enhance the way people work and live. Learn more at renesas.com. Follow us on LinkedIn, Facebook, Twitter, YouTube, and Instagram.
The statements in this press release with respect to the plans, strategies and financial outlook of Renesas and its consolidated subsidiaries (collectively 'we') are forward-looking statements involving risks and uncertainties. Such forward-looking statements do not represent any guarantee by management of future performance. In many cases, but not all, we use such words as 'aim,' 'anticipate,' 'believe,' 'continue,' 'endeavor,' 'estimate,' 'expect,' 'initiative,' 'intend,' 'may,' 'plan,' 'potential,' 'probability,' 'project,' 'risk,' 'seek,' 'should,' 'strive,' 'target,' 'will' and similar expressions to identify forward-looking statements. You can also identify forward-looking statements by discussions of strategy, plans or intentions. These statements discuss future expectations, identify strategies, contain projections of our results of operations or financial condition, or state other forward-looking information based on our current expectations, assumptions, estimates and projections about our business and industry, our future business strategies and the environment in which we will operate in the future. Known and unknown risks, uncertainties and other factors could cause our actual results, performance or achievements to differ materially from those contained or implied in any forward-looking statement, including, but not limited to, general economic conditions in our markets, which are primarily Japan, North America, Asia, and Europe; demand for, and competitive pricing pressure on, products and services in the marketplace; ability to continue to win acceptance of products and services in these highly competitive markets; and fluctuations in currency exchange rates, particularly between the yen and the U.S. dollar. Among other factors, downturn of the world economy; deteriorating financial conditions in world markets, or deterioration in domestic and overseas stock markets, may cause actual results to differ from the projected results forecast.
This press release is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither we nor our advisors or representatives are under an obligation to update, revise or affirm.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the 'BioMice' sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice ® platforms—including RenMab™ (fully human antibody), RenLite ® (common light chain), RenNano ® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice ® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice ® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit
Business Wire
2 hours ago
- Business Wire
The Open Group Launches The Open Group Open Digital Transformation™ Forum
SAN FRANCISCO--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. 'The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation,' commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. 'By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices.' Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. 'Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge,' said Steve Nunn, President and CEO of The Open Group. 'Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment.' To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries.
Business Wire
2 hours ago
- Business Wire
Bureau Veritas Partners with IFC's Building Resilience Index to Expand Resilience Verification Services Globally
PARIS--(BUSINESS WIRE)-- Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), has signed the first global verifier agreement to expand the reach and impact of the Building Resilience Index (BRI). Under this agreement, Bureau Veritas will serve as a verification partner for BRI across key emerging markets in Latin America, Africa, and East Asia and the Pacific. An innovation of IFC, a member of the World Bank Group, BRI is a web-based framework designed to help developers, investors, and policymakers identify risks to buildings posed by natural hazards and assess, improve, and disclose their resilience. Through this partnership with Bureau Veritas, BRI users will gain greater access to high-quality, third-party verification of climate-resilient construction practices, expanding trust and adoption of the tool in vulnerable regions where business continuity is increasingly threatened by extreme weather and related hazards. "We are delighted to become a Global Verifier of the Building Resilience Index. As climate phenomena intensify, it has become essential to integrate climate change adaptation into assets strategy. The signing of our global agreement with the International Finance Corporation marks a crucial step,' said Marc Roussel, Executive Vice President, Urbanization and Assurance at Bureau Veritas. 'Bureau Veritas has a long history as an independent third party mitigating natural and climate risks. Our network of experts will add a layer of trust so that stakeholders can rely on Building Resilience Index to evaluate vulnerability and effectiveness of adaptation strategies, worldwide.' In recent years, physical risks such as floods, cyclones, heatwaves, fires, earthquakes and landslides have posed major threats to business operations, disrupting supply chains, displacing workers and jobs, hurting productivity, and impacting insurance and financing terms. The BRI-Bureau Veritas partnership responds to a growing demand from businesses and governments for reliable tools that support risk mitigation, asset protection, and long-term economic stability. 'As businesses face increased risks to assets and infrastructure from natural disasters, the ability to assess and verify resilience is becoming a crucial element of operational and investment strategy,' said Diep Nguyen-van Houtte, Senior Manager of Climate Business at IFC. 'This partnership with Bureau Veritas strengthens the Building Resilience Index by ensuring that more clients—particularly in high-risk geographies—can benefit from credible, independently-verified insights into the resilience of their properties, adding a new tool to their climate adaptation arsenal.' By offering third-party verification through Bureau Veritas, the Building Resilience Index helps stakeholders: Protect operational continuity by identifying risks early and designing for resilience Safeguard jobs and livelihoods by minimizing disruption in vulnerable communities Enhance access to capital through better risk ratings and insurance alignment Improve public trust and accountability through independent performance validation This partnership builds on IFC's broader commitment to integrating adaptation into private sector development and enabling practical, market-driven solutions for climate resilience. BRI is funded by the Australian Government and was developed and piloted with seed funding from the Government of the Netherlands and the Rockefeller Foundation, in cooperation with leading organizations including the ARISE Private Sector Alliance for Disaster Resilient Societies, Build Change, FM Global, the Global Facility for Disaster Reduction and Recovery, Miyamoto International, and Resilience Action Fund. About Bureau Veritas: Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers' excellence and sustainability, the company innovates to help them navigate change. Created in 1828, Bureau Veritas' 84,000 employees deliver services in 140 countries. The company's technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability. Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI. For more information, visit and follow us on LinkedIn. About IFC: IFC — a member of the World Bank Group — is the largest global development institution focused on the private sector in emerging markets. We work in more than 100 countries, using our capital, expertise, and influence to create markets and opportunities in developing countries. In fiscal year 2024, IFC committed a record $56 billion to private companies and financial institutions in developing countries, leveraging private sector solutions and mobilizing private capital to create a world free of poverty on a livable planet. For more information, visit
